Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
In this review, the clinical pharmacology of high-dose doxorubicin is examined, and the pharmacokinetics of infusional doxorubicin at standard and high dose are compared. The data developed here, including recent clinical trials of high-dose infusional doxorubicin, demonstrate the safety and efficacy of doxorubicin administration at doses > or = 150 mg/m2 for patients with breast cancer and strongly suggest that the utility of this drug can be substantially increased with appropriate hematopoietic support.
Synold
T W
TW
Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Research Center, Duarte, CA 91010, USA.
Doroshow
J H
JH
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D009369:Neoplasms / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin